Eli Lilly has invested $2.75 billion in Insilico Medicine, a Hong Kong-based company, for AI-designed drugs. This significant deal highlights the growing trend of major pharmaceutical companies leveraging artificial intelligence for drug discovery. The investment is part of a larger wave, with Big Pharma committing over $13.6 billion in a single week to AI-driven biotechnology. AI
影响 Accelerates AI adoption in drug discovery, potentially leading to faster development of new medicines.
排序理由 Significant investment in an AI-focused biotech company by a major pharmaceutical firm.
在 Mastodon — sigmoid.social 阅读 →
AI 生成摘要 · Google Gemini · 来自 8 个来源。 我们如何撰写摘要 →
